Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.20 -3.9%	$3.24	$2.12 ▼ $5.80	$417.18M	1.97	1.50 million shs	2.51 million shs
CMPX Compass Therapeutics	$3.00 -4.8%	$2.43	$0.87 ▼ $4.08	$414.85M	1.48	992,208 shs	662,402 shs
HURA TuHURA Biosciences	$2.62 +3.6%	$2.81	$1.80 ▼ $7.93	$114.44M	0.17	262,411 shs	348,645 shs
ITOS iTeos Therapeutics	$10.26	$9.63	$4.80 ▼ $18.13	$392.69M	1.49	708,339 shs	528,642 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+4.74%	+23.53%	+67.33%	+35.48%
CMPX Compass Therapeutics	0.00%	+11.11%	+26.05%	+71.43%	+191.26%
HURA TuHURA Biosciences	0.00%	+13.91%	-2.96%	-36.87%	+261,999,900.00%
ITOS iTeos Therapeutics	0.00%	-0.29%	+2.60%	+57.60%	-39.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.2751 of 5 stars	3.5	3.0	0.0	0.0	0.0
CMPX Compass Therapeutics	2.2915 of 5 stars	3.6	1.0	0.6	5.0	0.0
HURA TuHURA Biosciences	1.6186 of 5 stars	3.7	0.0	2.4	0.0	0.0
ITOS iTeos Therapeutics	2.7768 of 5 stars	4.1	2.0	0.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	141.50% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.67	322.22% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	383.46% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	54.55% Upside

Current Analyst Ratings Breakdown

Latest HURA, CMPX, AQST, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	7.25	N/A	N/A	($0.66) per share	-6.36
CMPX Compass Therapeutics	$850K	488.05	N/A	N/A	$0.91 per share	3.30
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
ITOS iTeos Therapeutics	$35M	11.22	N/A	N/A	$16.16 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	291.69%	122.09%	10/6/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)

Latest HURA, CMPX, AQST, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ITOS iTeos Therapeutics	-$0.94	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	N/A	N/A	N/A	$11.32 million	N/A
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
CMPX Compass Therapeutics	N/A	8.33	8.33
HURA TuHURA Biosciences	N/A	3.00	3.00
ITOS iTeos Therapeutics	N/A	14.13	14.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CMPX Compass Therapeutics	68.43%
HURA TuHURA Biosciences	0.62%
ITOS iTeos Therapeutics	97.16%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
CMPX Compass Therapeutics	29.80%
HURA TuHURA Biosciences	0.20%
ITOS iTeos Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.03 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
HURA TuHURA Biosciences	N/A	43.68 million	43.59 million	N/A
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable

HURA, CMPX, AQST, and ITOS Headlines

Recent News About These Companies

Peapod Lane Capital LLC Increases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

July 10, 2025 | marketbeat.com

iTeos Therapeutics (ITOS): An Example of Biotech Liquidations

July 9, 2025 | finance.yahoo.com

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of "Hold" by Brokerages

July 3, 2025 | marketbeat.com

ITOS iTeos Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,883 Shares

June 12, 2025 | insidertrades.com

iTeos Therapeutics Inc.

June 11, 2025 | barrons.com

iTeos Therapeutics validates InvestingPro’s Fair Value analysis with 70% return

June 9, 2025 | uk.investing.com

Insider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells 38,227 Shares of Stock

June 7, 2025 | insidertrades.com

Stocks With Rising Relative Strength: iTeos Therapeutics

June 6, 2025 | msn.com

More bad news in biotech: Watertown cancer firm iTeos shutting down

June 4, 2025 | bostonglobe.comB

iTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value

May 30, 2025 | nasdaq.com

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

May 30, 2025 | zacks.com

Wedbush Downgrades iTeos Therapeutics (ITOS)

May 29, 2025 | msn.com

iTeos to Close Down After TIGIT Fail

May 29, 2025 | biospace.comB

iTeos to shut down operations after TIGIT setback and GSK exit

May 29, 2025 | thepharmaletter.comT

iTeos Therapeutics stock surges on wind-down news

May 28, 2025 | za.investing.com

iTeos Therapeutics Stock Jumps Following Operational Closure Announcement

May 28, 2025 | msn.com

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’

May 28, 2025 | msn.com

iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations

May 28, 2025 | finanznachrichten.de

ITeos Therapeutics Shares Surge on Wind Down of Operations

May 28, 2025 | marketwatch.com

iTeos plans to shut down operations after cancer therapy setback

May 28, 2025 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, CMPX, AQST, and ITOS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.20 -0.17 (-3.89%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.24 +0.04 (+0.95%)

As of 07/18/2025 07:58 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Compass Therapeutics NASDAQ:CMPX

$3.00 -0.15 (-4.76%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.01 +0.01 (+0.20%)

As of 07/18/2025 07:04 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

TuHURA Biosciences NASDAQ:HURA

$2.62 +0.09 (+3.56%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.61 -0.01 (-0.38%)

As of 07/18/2025 07:55 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

iTeos Therapeutics NASDAQ:ITOS

$10.26 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$10.33 +0.07 (+0.67%)

As of 07/18/2025 04:24 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time